SynthesisThe oncologist2025
Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Synthesis in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Interleukin-8 in health and disease.Molecular biomedicine · 2026Review
- Distinct Inflammatory and Dissemination Signatures Defined by Macrophage Migration Inhibitory Factor (MIF), Interleukin-8 (IL-8/CXCL8), and Stem Cell Factor (SCF) in Pancreatic Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.Translational andrology and urology · 2026Article
- Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer.Frontiers in immunology · 2026Review
- Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
BACKGROUND AND
objectiveInterleukin-8 (IL-8) is a chemokine involved in inflammation and primary immune response, playing a key role in recruiting neutrophils. IL-8 is produced by several cell types, including immune cells and certain cancer cells. Elevated levels of IL-8 have been associated with a poorer outcome in several tumors and have been related to advanced diseases, treatment resistance, and possibly promoting neo angiogenesis and immune cell recruitment. In the renal cell carcinoma (RCC), the prognostic role of IL-8 has not been settled.
methodsFrom January 1, 2008 to June 18, 2024, PubMed, Embase, and Scopus databases were searched for all studies investigating the potential prognostic role of IL-8 in RCC. All studies were rated according to the Newcastle-Ottawa Scale. Progression-free survival (PFS) and overall survival (OS) were analyzed as clinical outcomes, and a meta-analysis was performed for both. KEY FINDINGS AND LIMITATIONS: Overall, six papers met the predefined inclusion criteria, with final analyses demonstrating that high IL-8 levels significantly correlate with worse prognosis in RCC, with a statistically shorter PFS (hazard ratio [HR]: 1.27, 95% confidence interval [CI]: 1.01-1.59; P = 0.037) and statistically shorter OS (HR: 1.85, 95% CI: 1.21-2.84; P = .001). Prospective randomized clinical trials are also necessary to investigate the predictive role of IL-8 in the contemporary treatment scenario of RCC to improve clinical decision-making.
conclusionsThis meta-analysis demonstrates the significant prognostic role of IL-8 in RCC, suggesting that IL-8 could be used to refine the prognostic RCC assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.